Literature DB >> 15990612

The importance of models in glaucoma research.

Robert N Weinreb1, James D Lindsey.   

Abstract

Experimental models have enhanced our understanding of the biology of glaucoma. Moreover, they have enabled the testing of potential therapies prior to the initiation of human trials. Each have advantages and limitations. In vitro cell and organ culture offer direct cellular accessibility and microenvironmental control, as well as efficient comparison between many experimental conditions or potential therapeutic compounds. However, they generally have less relevance to clinical glaucoma than in vivo models. Rat models allow moderate sized investigations of intact biological systems that have greater relevance to glaucoma than in vitro experiments, but less than primate experiments. Mouse models are similar to rat models but have the advantage of investigating mutant and transgenic strains mimicking specific aspects of glaucoma that are not available in other model systems. Primate models of glaucoma generally are the most relevant to human glaucoma but must be limited in scope because of availability and the high cost of experimentation.

Entities:  

Mesh:

Year:  2005        PMID: 15990612     DOI: 10.1097/01.ijg.0000169395.47921.02

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  20 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Evaluation of retinal nerve fiber layer thickness and axonal transport 1 and 2 weeks after 8 hours of acute intraocular pressure elevation in rats.

Authors:  Carla J Abbott; Tiffany E Choe; Theresa A Lusardi; Claude F Burgoyne; Lin Wang; Brad Fortune
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-04       Impact factor: 4.799

3.  Postnatal elongation of eye size in DBA/2J mice compared with C57BL/6J mice: in vivo analysis with whole-eye OCT.

Authors:  Tsung-Han Chou; Omer P Kocaoglu; David Borja; Marco Ruggeri; Stephen R Uhlhorn; Fabrice Manns; Vittorio Porciatti
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

4.  Evaluation of rebound tonometry in non-human primates.

Authors:  Elizabeth J Elsmo; Julie A Kiland; Paul L Kaufman; Gillian J McLellan
Journal:  Exp Eye Res       Date:  2011-02-16       Impact factor: 3.467

Review 5.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Cell proliferation and interleukin-6-type cytokine signaling are implicated by gene expression responses in early optic nerve head injury in rat glaucoma.

Authors:  Elaine C Johnson; Thomas A Doser; William O Cepurna; Jennifer A Dyck; Lijun Jia; Ying Guo; Wendi S Lambert; John C Morrison
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-25       Impact factor: 4.799

7.  [Toxicity of a new moistening agent and preservative in vitro].

Authors:  K Kasper; C Kremling; G Geerling
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

8.  Laser-induced ocular hypertension in albino CD-1 mice.

Authors:  Christine T Fu; David Sretavan
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-08       Impact factor: 4.799

9.  Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control.

Authors:  Yolandi van der Merwe; Matthew C Murphy; Jeffrey R Sims; Muneeb A Faiq; Xiao-Ling Yang; Leon C Ho; Ian P Conner; Yu Yu; Christopher K Leung; Gadi Wollstein; Joel S Schuman; Kevin C Chan
Journal:  Neurotherapeutics       Date:  2021-04-13       Impact factor: 7.620

10.  Soluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucoma.

Authors:  Emmanuel S Buys; Yu-Chieh Ko; Clemens Alt; Sarah R Hayton; Alexander Jones; Laurel T Tainsh; Ruiyi Ren; Andrea Giani; Maeva Clerté; Emma Abernathy; Robert E T Tainsh; Dong-Jin Oh; Rajeev Malhotra; Pankaj Arora; Nadine de Waard; Binglan Yu; Raphael Turcotte; Daniel Nathan; Marielle Scherrer-Crosbie; Stephanie J Loomis; Jae H Kang; Charles P Lin; Haiyan Gong; Douglas J Rhee; Peter Brouckaert; Janey L Wiggs; Meredith S Gregory; Louis R Pasquale; Kenneth D Bloch; Bruce R Ksander
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.